1-(4-氯苯基)-2-(甲基氨基)乙酮 | 77914-62-6

• 分子结构分类: 有机化合物 - 有机氧化合物
• 中文名称: 1-(4-氯苯基)-2-(甲基氨基)乙酮
• 英文名称: 1-(4-chloro-phenyl)-2-methylamino-ethanone
• 英文别名: Ethanone, 1-(4-chlorophenyl)-2-(methylamino)-；1-(4-chlorophenyl)-2-(methylamino)ethanone
• CAS: 77914-62-6
• 化学式: C₉H₁₀ClNO
• 分子量: 183.637
• InChiKey: HUXNDCBFXVPCEB-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  29.1
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-(4-氯苯基)-2-(甲基氨基)乙酮 、 甲乙酐 以 苯 为溶剂， 生成 N-(2-(4-chlorophenyl)-2-oxoethyl)-N-methylformamide
  参考文献：
  名称：

  Scalable synthesis of imidazole derivatives

  摘要：

  咪唑衍生物，含有它们的组合物，制备它们的方法，包括选择性区域放大合成方法，以及使用它们的方法。

  公开号：

  US20050250948A1
• 作为产物：
  描述：

  (4-chlorophenyl)-[(2R,3R)-1-methyl-3-phenylaziridin-2-yl]methanone 在 三氟化硼 、 水 作用下， 以 丙酮 为溶剂， 生成 1-(4-氯苯基)-2-(甲基氨基)乙酮
  参考文献：
  名称：

  Synthesis and stereochemistry of 2,2,3-trimethyl-5-aryl-4-aroyloxazolidines

  摘要：

  DOI：

  10.1007/bf00507085

文献信息

• Asymmetric Hydrogenation of α-Primary and Secondary Amino Ketones: Efficient Asymmetric Syntheses of (−)-Arbutamine and (−)-Denopamine
  作者：Gao Shang、Duan Liu、Scott E. Allen、Qin Yang、Xumu Zhang

  DOI：10.1002/chem.200700594

  日期：2007.9.17

  Two beta-receptor agonists (-)-denopamine and (-)-arbutamine were prepared in good yields and enantioselectivities by asymmetric hydrogenation of unprotected amino ketones for the first time by using Rh catalysts bearing electron-donating phosphine ligands. A series of alpha-primary and secondary amino ketones were synthesized and hydrogenated to produce various 1,2-amino alcohols in good yields and

  通过使用带有给电子膦配体的Rh催化剂进行不保护的氨基酮的不对称氢化，以高收率和对映选择性制备了两种β受体激动剂（-）-地巴胺和（-）-arbutamine。合成了一系列的α-伯氨基和仲氨基酮并进行氢化，以高收率和良好的对映选择性生产出各种1,2-氨基醇。这种Rh电子给体的膦催化的不对称氢化反应代表了手性氨基醇不对称合成的最有希望和最方便的方法之一。
• INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF
  申请人：OKUYAMA Masahiro

  公开号：US20110251385A1

  公开（公告）日：2011-10-13

  The present invention relates to a production method of an optically active morpholine compound represented by the formula 10, which includes the following steps: wherein each symbol is as defined in the specification. The present invention also relates to a production method of an compound represented by the formula 55, which includes the following steps: wherein each symbol is as defined in the specification. According to the production method of the present invention, an optically active 2-aryl-substituted morpholine compound and 3-oxo-3-(pyrimidin-4-yl)propionate, which are important as starting materials for synthesizing 2-(2-arylmorpholin-4-yl)-1-methyl-1H-[4,4′]bipyrimidinyl-6-one having a tau protein kinase 1 inhibitory activity and useful as a therapeutic drug for Alzheimer's disease and the like, can be produced in a high yield by an industrially advantageous method.

  本发明涉及一种光学活性吗啉化合物的生产方法，其由公式10表示，包括以下步骤：其中每个符号如规范中所定义。本发明还涉及一种由公式55表示的化合物的生产方法，其包括以下步骤：其中每个符号如规范中所定义。根据本发明的生产方法，可以通过一种工业上有利的方法高产地生产重要的起始材料，即光学活性2-芳基取代吗啉化合物和3-氧代-3-(嘧啶-4-基)丙酸酯，用于合成具有tau蛋白激酶1抑制活性的2-(2-芳基吗啉-4-基)-1-甲基-1H-[4,4′]联吡啶基-6-酮，该化合物对阿尔茨海默病等有用作用的治疗药物。
• TRICYCLIC PYRIDO-CARBOXAMIDE DERIVATIVES AS ROCK INHIBITORS
  申请人：BRISTOL-MYERS SQUIBB COMPANY

  公开号：US20160152628A1

  公开（公告）日：2016-06-02

  The present invention provides compounds of Formula (I): or stereoisomers, tautomers, or pharmaceutically acceptable salts thereof, wherein all the variables are as defined herein. These compounds are selective ROCK inhibitors. This invention also relates to pharmaceutical compositions comprising these compounds and methods of treating cardiovascular, smooth muscle, oncologic, neuropathologic, autoimmune, fibrotic, and/or inflammatory disorders using the same.

  本发明提供了式（I）的化合物：或其立体异构体，互变异构体或药学上可接受的盐，其中所有变量如本文所定义。这些化合物是选择性ROCK抑制剂。本发明还涉及包含这些化合物的制药组合物以及使用它们治疗心血管，平滑肌，肿瘤，神经病理，自身免疫，纤维化和/或炎症性疾病的方法。
• NOVEL COMPOUND HAVING CANCER METASTASIS INHIBITORY ACTIVITY, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR INHIBITING CANCER METASTASIS AND INVASION OR TREATING COLORECTAL CANCER, COMPRISING COMPOUND
  申请人：Cellgentek Co., Ltd

  公开号：EP4019495A1

  公开（公告）日：2022-06-29

  The present invention provides a novel compound that increases KAI1 promoter activity, a pharmaceutically acceptable salt thereof, and a composition for inhibiting cancer metastasis and invasion or treating colorectal cancer containing the same.

  本发明提供了一种新的化合物，可以增加KAI1启动子活性，其药学上可接受的盐，以及用于抑制癌症转移和侵袭或治疗结肠癌的组合物。
• 5,6-dihydro(1H-indolo(3,2-c)quinoline-6,4-piperidines)and related compounds, a process for their preparation and their use as medicaments
  申请人：HOECHST-ROUSSEL PHARMACEUTICALS INCORPORATED

  公开号：EP0407898A1

  公开（公告）日：1991-01-16

  There are disclosed compounds having the formula where n is 0, 1, or 2; p and q are each independently 1, 2 or 3; each X and each Y are independently hydrogen, loweralkyl, loweralkoxy, halogen, hydroxy, nitro, amino, loweralkylamino, diloweralkylamino, trifluoromethyl or loweralkylthio; R₁ and R₂ are each independently hydrogen or loweralkyl; and R₃ is hydrogen, loweralkyl, loweralkylcarbonyl, arylloweralkyl or aminocarbonyl; which are useful as analgesic, antipsychotic and anticonvulsant agents , and a process for their preparation.

  所公开的化合物具有如下式子 式中 n为0、1或2 p 和 q 各自独立地为 1、2 或 3； 每个 X 和每个 Y 独立地为氢、低级烷基、低级烷氧基、卤素、羟基、硝基、氨基、低 级烷基氨基、稀释低级烷基氨基、三氟甲基或低级烷硫基； R₁ 和 R₂ 各自独立地为氢或低级烷基；以及 R₃ 是氢、低级烷基、低级烷基羰基、芳基低级烷基或氨基羰基； 可用作镇痛剂、抗精神病剂和抗惊厥剂的化合物及其制备方法。